Skip to content

Study · Observational study · 2025

6 results

Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database.

Hankosky ER, Chinthammit C, Meeks A, Huang A, Ward JM, Mojdami D, Gibble TH

Diabetes, obesity & metabolism25 Feb 2025Cited by 19 (Europe PMC)

PMID39996368 (opens in a new tab)PMCIDPMC11964993 (opens in a new tab)DOI10.1111/dom.16290 (opens in a new tab)PepBankPUB-39996368
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyOther

    In US adults without type 2 diabetes, 55.4% of the utilization cohort were persistent on tirzepatide.

    In plain wordsIn US adults without type 2 diabetes, just over half stayed on tirzepatide in the observation period.

    Peptide
    Tirzepatide
    Outcome
    Not applicablePersistence on tirzepatide
    Study

    n: not reported in source

    Outcome group
    Patterns of use · Whole body
    Studied dose
    Dose not stated

    Measurements

    Persistence
    55.4%
    utilization cohort

    Source sentences

    Summary
    Persistence in the utilization cohort was 55.4%
    1 context sentence
    Summary · context
    This retrospective, observational study used Optum's de-identified Market Clarity database (index date: first-observed tirzepatide claim; index period: 13 May 2022-30 September 2023).
  2. 02HumanObservational studyOther

    In US adults without type 2 diabetes, 30.8% switched to a different AOM/GLP-1 RA analogue or restarted tirzepatide after discontinuation.

    In plain wordsIn US adults without type 2 diabetes, nearly one third switched to another weight drug or restarted tirzepatide after stopping.

    Peptide
    Tirzepatide
    Outcome
    Not applicableSwitching to another anti-obesity medication or restarting
    Study

    n: not reported in source

    Outcome group
    Patterns of use · Whole body
    Studied dose
    Dose not stated

    Measurements

    Switched or restarted
    30.8%
    utilization cohort

    Source sentences

    Summary
    30.8% switched to a different AOM/GLP-1 RA analogue or restarted tirzepatide after discontinuation, and by the sixth prescription fill, 74.2% were on <10 mg tirzepatide.
    1 context sentence
    Summary · context
    This retrospective, observational study used Optum's de-identified Market Clarity database (index date: first-observed tirzepatide claim; index period: 13 May 2022-30 September 2023).
  3. 03HumanObservational studyOther

    In US adults without type 2 diabetes, 74.2% were on less than 10 mg tirzepatide by the sixth prescription fill.

    In plain wordsIn US adults without type 2 diabetes, about three in four were still on a dose below 10 mg by their sixth fill.

    Peptide
    Tirzepatide
    Outcome
    Not applicableProportion on less than 10 mg by sixth fill
    Study

    n: not reported in source

    Outcome group
    Patterns of use · Whole body
    Studied dose
    Dose not stated

    Measurements

    On <10 mg tirzepatide
    74.2%
    sixth prescription fill

    Source sentences

    Summary
    by the sixth prescription fill, 74.2% were on <10 mg tirzepatide.
    1 context sentence
    Summary · context
    This retrospective, observational study used Optum's de-identified Market Clarity database (index date: first-observed tirzepatide claim; index period: 13 May 2022-30 September 2023).
  4. 04HumanObservational studyEfficacy outcome

    In US adults without type 2 diabetes who stayed on tirzepatide, mean weight reduction was 11.9% at 6 months post-index.

    In plain wordsIn US adults without type 2 diabetes who stayed on tirzepatide, average weight fell by 11.9% after 6 months.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMean weight reduction at 6 months
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Mean weight reduction
    11.9%
    6 months post-index

    Source sentences

    Summary
    Mean weight reduction in the effectiveness cohort was 11.9% at 6 months post-index
    1 context sentence
    Summary · context
    This retrospective, observational study used Optum's de-identified Market Clarity database (index date: first-observed tirzepatide claim; index period: 13 May 2022-30 September 2023).
  5. 05HumanObservational studyEfficacy outcome

    In US adults without type 2 diabetes who stayed on tirzepatide, 85.8% had a weight reduction of at least 5%.

    In plain wordsIn US adults without type 2 diabetes who stayed on tirzepatide, most lost at least 5% of their weight.

    Peptide
    Tirzepatide
    Outcome
    DecreaseProportion with weight reduction of 5% or more
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Weight reduction >=5%
    85.8%
    effectiveness cohort

    Source sentences

    Summary
    (≥5%: 85.8%; ≥10%: 61.5%).
    1 context sentence
    Summary · context
    This retrospective, observational study used Optum's de-identified Market Clarity database (index date: first-observed tirzepatide claim; index period: 13 May 2022-30 September 2023).
  6. 06HumanObservational studyEfficacy outcome

    In US adults without type 2 diabetes who stayed on tirzepatide, 61.5% had a weight reduction of at least 10%.

    In plain wordsIn US adults without type 2 diabetes who stayed on tirzepatide, more than half lost at least 10% of their weight.

    Peptide
    Tirzepatide
    Outcome
    DecreaseProportion with weight reduction of 10% or more
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Weight reduction >=10%
    61.5%
    effectiveness cohort

    Source sentences

    Summary
    ≥10%: 61.5%).
    1 context sentence
    Summary · context
    This retrospective, observational study used Optum's de-identified Market Clarity database (index date: first-observed tirzepatide claim; index period: 13 May 2022-30 September 2023).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.